Telix Pharmaceuticals Limited has announced that the U.S. Food and Drug Administration has accepted its resubmitted New Drug Application (NDA) for TLX101-Px, an investigational imaging agent designed to improve the detection and monitoring of glioma, a type of brain cancer. The agency has set a target decision date of September 11, 2026, under the Prescription Drug User Fee Act (PDUFA) timeline.
TLX101-Px, also known as Pixclara (Floretyrosine F 18 or 18F-FET), is a positron emission tomography (PET) imaging agent intended to help clinicians distinguish between tumor progression and treatment-related changes in both adult and pediatric patients with glioma. If approved, the drug could address a significant unmet medical need in neuro-oncology, where accurately assessing disease status following treatment remains a major clinical challenge.
Experts in the field have emphasized the importance of improved imaging tools. Physicians note that differentiating between active tumor growth and changes caused by therapies such as radiation or chemotherapy is often difficult using conventional imaging methods. The use of 18F-FET PET imaging has already been widely adopted in international clinical guidelines, highlighting its potential value in routine care.
The investigational agent has received both Orphan Drug and Fast Track designations from the FDA, reflecting its potential to address a rare and serious condition while expediting its development and review process. These designations are typically granted to therapies that show promise in treating conditions with limited available options.
Clinical collaborators have welcomed the FDA’s decision to accept the application, noting that broader access to advanced imaging techniques could significantly improve patient management. Researchers involved in supporting the application highlighted that years of clinical data have demonstrated the utility of FET-PET imaging in guiding treatment decisions and monitoring disease progression.
Telix executives described the FDA’s acceptance as a key regulatory milestone for the company. They indicated that the organization will continue working closely with regulators to advance the application and, if approved, bring the imaging agent to market as quickly as possible.
Despite the progress, Telix has stated that its financial guidance for fiscal year 2026 does not currently include any projected revenue from TLX101-Px, underscoring that approval is still pending.
The development reflects a broader push within oncology to enhance diagnostic precision, particularly in complex cancers like glioma, where treatment decisions heavily depend on accurate imaging. If approved, TLX101-Px could play a critical role in improving outcomes by enabling more informed and timely clinical interventions.